9日投资提示：康泰生物终止与阿斯利康合资设立疫苗企业

Group 1 - The core viewpoint of the article is the recent developments in convertible bonds and the termination of a joint venture in the vaccine sector by Kangtai Biological [1][2][4][6] Group 2 - Kangtai Biological has terminated its joint venture with AstraZeneca to establish a vaccine company, indicating a strategic shift in its business operations [1] - Hongchuan Convertible Bond has announced a downward adjustment, while other bonds such as Feng 21, Mengsheng, and Rong 23 have been subject to strong redemption [1][2] - Daimei Convertible Bond will not undergo strong redemption, and Jianlong Convertible Bond will not be adjusted downwards [1][2] - New stock subscription for Tongbao Optoelectronics is available on the Beijing Stock Exchange [1] - The article provides detailed information on various convertible bonds, including their current prices, redemption prices, and remaining scales, highlighting the market dynamics [4][6]